As of Apr 8, 2019 Myomo Inc (NYSEAMERICAN:MYO) Sellers Declined Their Shorts By 6.82%

Myomo Inc (NYSEAMERICAN:MYO) registered a decrease of 6.82% in shares shorted. FINRA published in April MYO’s total 508,100 shares shorted. The 545,300 previous shares are down with 6.82%. Myomo Inc (NYSEAMERICAN:MYO) has 137,500 shares average volume. It’ll cost 4 days for MYO to restore its former position.

MYO is reaching $1.19 during the last trading session, after increased 0.85%.Currently Myomo, Inc. is downtrending after 73.43% change in last April 8, 2018. MYO has 22,067 shares volume. MYO underperformed by 77.80% the S&P 500.

Myomo, Inc., a commercial stage medical robotics Company, provides expanded mobility solutions for patients suffering from neurological disorders and upper limb paralysis in the United States.The company has $20.33 million market cap. The firm develops and markets MyoPro, a myoelectric elbow/wrist/hand orthosis that supports an impaired hands and arms of individuals due to a brachial plexus injury, stroke, spinal cord injury, traumatic brain injury, amyotrophic lateral sclerosis, multiple sclerosis, and other upper limb neuromuscular deficits.Last it reported negative earnings.

For more Myomo, Inc. (NYSEAMERICAN:MYO) news released briefly go to: Businesswire.com, Streetinsider.com, Businesswire.com, Businesswire.com or Businesswire.com. The titles are as follows: “Myomo, Inc. Prices Public Offering of Common Stock – Business Wire” released on February 08, 2019, “Myomo (MYO) Announces Proposed Public Offering of Common Stock – StreetInsider.com” on February 07, 2019, “Myomo Announces Third Quarter 2018 Financial Results – Business Wire” with a publish date: November 05, 2018, “Myomo Announces Participation at Two Upcoming Investor Conferences – Business Wire” and the last “Myomo Announces CFO Succession – Business Wire” with publication date: February 06, 2019.

Myomo, Inc. (NYSEAMERICAN:MYO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.